Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsDrreddyslaboratories

    At Moneycontrol, the Results page helps you effectively track corporate announcements and results for various listed companies across both India and abroad. With our Results page, you can keep abreast with an updated, comprehensive view of all the profit/loss statements, company spendings, AGM outcomes, and quarterly and annual results from all these listed companies. Additionally, Moneycontrol also regularly tracks international MNCs listed on NASDAQ and Asian bourses, including popular companies like Apple, Google, Alibaba. Apart from finding solid copies of company results, stock movements consequent to these company results, expectations, and analytical post results copies, you will also find copies and articles detailing the earnings, impact, and all major announcements made to media/exchanges by these companies, so that you do not miss anything. We also provide you with concrete data points to help you spot profitable trades, stock build-ups, and bulk deals. At Moneycontrol, we also cover analysts/investors meetings; scrutinise results and data and BSE/NSE reports or news. The copies are not just full of information and data, but are also adequately supplemented with expert views, investor opinions, extensive interviews, videos, and a huge variety of explainers, analyses, and informative slideshows to help you gauge the market and make investment decisions in the best possible manner. More

    Jump to

    • Dr Reddy's Labs Q4 profit may jump over 5-fold but revenue seen down 2%

      Revenue during the quarter may fall 2 percent year-on-year to Rs 3,680 crore due to lower US growth.

    • Dr. Reddy’s Q4 PAT seen up 6.3% to Rs 499.9 cr: ICICI Securities

      Net Sales are expected to increase by 2.5 percent Q-o-Q (up 1.2 percent Y-o-Y) to Rs 3800.9 crore, according to ICICI Securities. Dr. Reddy’s to report net profit at 3800.9 crore up 1.2% quarter-on-quarter.

    • Good Q3 but Dr Reddy's still far from sustainable growth: Expert

      Surajit Pal, Research Analyst at Prabhudas Lilladher, said the pharma sector is undergoing a transition and all the large midcaps will underperform.

    • Q4 to be lean qtr for US biz due to delayed launches: Dr Reddy's

      The pharma major reported third quarter earnings on Saturday. While revenues declined, the drop was in-line with expectations and was overall an operationally strong quarter.

    • Dr Reddy's Q3 profit seen down 37%, US biz likely to be sluggish

      US business is likely to be sluggish due to lack of quality approvals during the quarter and increasing competition in key drugs such as Dacogen, Valcyte and Vidaza generic.

    • Dr. Reddy‘s Q3 PAT seen up 28.4% to Rs 380 cr: HDFC Securities

      Net Sales are expected to increase by 4.6 percent Q-o-Q (down 5.4 percent Y-o-Y) to Rs 3750 crore, according to HDFC Securities.

    • Dr. Reddy‘s Q3 PAT seen up 18.8% to Rs 388 cr: ICICI Securities

      Net Sales are expected to increase by 7.4 percent Q-o-Q (down 2.9 percent Y-o-Y) to Rs 3851.4 crore, according to ICICI Securities.

    • Dr. Reddy‘s Q3 PAT seen up 14.3% to Rs 353.1 cr: KR Choksey

      Net Sales are expected to increase by 0.4 percent Q-o-Q (down 8.5 percent Y-o-Y) to Rs 3632 crore, according to KR Choksey.

    • DRL Q2 in line with view, coming qtrs may not be great: experts

      The earning numbers a mostly in line with estimates and Angel Broking keeps a neutral rating on the stock, says Sarabjit Kour Nangra of Angel Broking.

    • Dr Reddy's Labs Q2 profit may sink 59%, US sales seen down 20%

      Performance of Dr Reddy's Laboratories in July-September quarter is expected to be weak as profit is likely to plunge 59 percent year-on-year to Rs 298 crore on poor operational performance.

    • Dr. Reddy's Labs Q2 PAT seen up 11.1% to Rs 170.5 cr: Centrum

      Net Sales are expected to increase by 2.9 percent Q-o-Q (down 16.9 percent Y-o-Y) to Rs 3316 crore, according to Centrum.

    • Pharma cos may report subdued performance in Q2 FY17: Report

      Domestic pharmaceutical companies are likely to report subdued sales, EBITDA and PAT figures in the second quarter of this fiscal, even as the formulations business may see a strong recovery, Reliance Securities said in its report.

    • New launches in H2FY17 will boost growth: Dr Reddy's

      The fall in revenue and profits in the first quarter was due to lack of launches in the US, says Saumen Chakraborty, CFO of Dr Reddy‘s. The company launched its first product in the US in July.

    • Indian assets doing well; hopeful of few launches in US: DRL

      For the first quarter ended June, Dr Reddy‘s Laboratories missed estimates on all counts. Revenue declined 14 percent to Rs 3,222.5 crore in the quarter ended June 2016 from Rs 3,752.2 crore in same period last year.

    • No disturbing trend in Dr Reddy's numbers except topline: Expert

      Shetty says that she has her doubts on a possible revival of revenues saying that the eight drugs bought from Teva for the US market, will take till 2019 to affect Dr Reddy's revenues.

    • Here are Edelweiss' 3 concerns that could hit Dr Reddy's

      An increase in competition in the US business is going to lead to pricing pressure for Dr Reddy's Laboratories. This can lead to a fall in margins for the pharma company by about 250-350 basis points, says Deepak Malik, Associate Director, Edelweiss Securities.

    • US biz may drag Dr Reddy's Q1, net seen down 27% at Rs 456 cr

      US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.

    • Dr Reddy‘s Q1 PAT seen up by 492.8% at Rs 442.2 cr: Religare

      Sales are expected to decrease by 1.2 percent Q-o-Q (down 1.2 percent Y-o-Y) to Rs 3712.3 crore, according to Religare Research.

    • Dr. Reddy's Q1 PAT seen up 584.3% to Rs 510.5 cr: Edelweiss

      Net Sales are expected to increase by 2.9 percent Q-o-Q (up 2.9 percent Y-o-Y) to Rs 3865 crore, according to Edelweiss

    • Q1 earnings: Which sectors will do well, which won't?

      In an interview with CNBC-TV18, Pankaj Pandey of ICICI Direct talked about the brokerage's expectations from the first quarter earnings season and outlined his view on various sectors.

    • New launches to drive growth in second quarter: Dr Reddy's

      There are approvals pending, but not from its Srikakulam plant. But improving quality checks at pharma's plants would be a high priority, says GV Prasad, CEO, Dr Reddy‘s.

    • Venezuelan write-offs hit Dr Reddy's Q4 numbers:Experts

      Disappointing performance in the topline and ongoing currency issues have hurt Q4 numbers of the pharma company," says Mayuresh Joshi of Angel Broking.

    • Dr Reddy's Q4 profit may rise 6%, warning letters resolution key

      During the period, EBITDA may grow 11.2 percent to Rs 897 crore versus Rs 806.4 crore while margins may stand at 23 percent versus 21 percent.

    • See huge opportunity in Venezuela; US supply not restricted: DRL

      Saumen Chakraborty, CFO, Dr Reddy's, says the company has been calibrating sales in Venezuala where the market and capacity is huge.

    • Dr Reddy's Q3 profit seen up 13%, Russia & CIS may hurt revenue

      Revenue is seen rising 4.3 percent to Rs 4,007 crore in quarter ended December 2015 compared to Rs 3,843 crore in corresponding quarter of last fiscal.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347